These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 16501420)

  • 1. Results of severe sepsis treatment program using recombinant human activated protein C in Poland.
    Kübler A; Mayzner-Zawadzka E; Durek G; Gaszyński W; Karpel E; Mikaszewska-Sokolewicz M; Majak P
    Med Sci Monit; 2006 Mar; 12(3):CR107-12. PubMed ID: 16501420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study.
    Kanji S; Perreault MM; Chant C; Williamson D; Burry L
    Intensive Care Med; 2007 Mar; 33(3):517-23. PubMed ID: 17325837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.
    Ely EW; Laterre PF; Angus DC; Helterbrand JD; Levy H; Dhainaut JF; Vincent JL; Macias WL; Bernard GR;
    Crit Care Med; 2003 Jan; 31(1):12-9. PubMed ID: 12544987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
    Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; McL Booth FV
    Surgery; 2006 Nov; 140(5):726-39. PubMed ID: 17084715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of drotrecogin alfa (activated) in solid organ transplant patients: a case series.
    Berkman S; Weimert NA; Taber DJ; Baillie GM; Lin A; Baliga P; Chavin KD
    Transpl Infect Dis; 2009 Jun; 11(3):269-76. PubMed ID: 19392728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drotrecogin alfa (activated) treatment of older patients with severe sepsis.
    Ely EW; Angus DC; Williams MD; Bates B; Qualy R; Bernard GR
    Clin Infect Dis; 2003 Jul; 37(2):187-95. PubMed ID: 12856210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drotrecogin alfa (activated) for severe sepsis: could we consider a shorter treatment period in patients with a favorable course?
    Ahishakiye D; Lorent S; De Backer D; Gottignies P; Vincent JL
    J Crit Care; 2009 Dec; 24(4):590-4. PubMed ID: 19577419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis.
    Barie PS; Hydo LJ; Shou J; Eachempati SR
    Surg Infect (Larchmt); 2006; 7 Suppl 2():S77-80. PubMed ID: 16895513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drotrecogin alfa (activated): a pharmacoeconomic review of its use in severe sepsis.
    Frampton JE; Foster RH
    Pharmacoeconomics; 2004; 22(7):445-76. PubMed ID: 15137883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice.
    Ridley S; Lwin A; Wyncoll D; Lippett S; Watson D; Gunning K; Higgins D
    Eur J Anaesthesiol; 2008 Mar; 25(3):211-6. PubMed ID: 18031590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bleeding complications with Drotrecogin alfa activated (Xigris): a retrospective review of 31 operative and 68 non-operative patients with severe sepsis.
    Taylor BJ; Lee SJ; Waxman K
    Am Surg; 2008 Oct; 74(10):898-901. PubMed ID: 18942609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression.
    Kalil AC; LaRosa SP
    Lancet Infect Dis; 2012 Sep; 12(9):678-86. PubMed ID: 22809883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ADDRESS (ADministration of DRotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: one-year safety and efficacy evaluation.
    Laterre PF; Abraham E; Janes JM; Trzaskoma BL; Correll NL; Booth FV
    Crit Care Med; 2007 Jun; 35(6):1457-63. PubMed ID: 17452935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 90-day follow-up of patients treated with Drotrecogin Alfa (activated) for severe sepsis: a Belgian open label study.
    Decruyenaere J; De Backer D; Spapen H; Laterre PF; Raemaekers J; Rogiers P; Trine H; Sartral M; Haentjens T; Wagner T
    Acta Clin Belg; 2009; 64(1):16-22. PubMed ID: 19317237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Questionable efficacy and safety of activated drotrecogin alpha (activated protein C) in the treatment of severe sepsis].
    Bartelink AK
    Ned Tijdschr Geneeskd; 2006 Feb; 150(7):352-4. PubMed ID: 16523795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risks and benefits of activated protein C treatment for severe sepsis.
    Warren HS; Suffredini AF; Eichacker PQ; Munford RS
    N Engl J Med; 2002 Sep; 347(13):1027-30. PubMed ID: 12324562
    [No Abstract]   [Full Text] [Related]  

  • 17. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
    Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; Booth FV
    Surgery; 2007 Apr; 141(4):548-61. PubMed ID: 17431957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis.
    McCoy C
    Expert Opin Drug Saf; 2004 Nov; 3(6):625-37. PubMed ID: 15500421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety.
    Laterre PF; Nelson DR; Macias W; Abraham E; Sashegyi A; Williams MD; Levy M; Levi M; Utterback B; Vincent JL
    J Crit Care; 2007 Jun; 22(2):142-52. PubMed ID: 17548026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A registry of patients treated with drotrecogin alfa (activated) in Belgian intensive care units--an observational study.
    Vincent JL; Laterre PF; Decruyenaere J; Spapen H; Raemaekers J; Damas F; Rogiers P; Sartral M; Haentjens T; Nelson D; Janes J
    Acta Clin Belg; 2008; 63(1):25-30. PubMed ID: 18386762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.